According to the Complaint, Evolus, Inc. is a medical aesthetic company formed with the sole aim to develop and introduce a cheaper alternative to Botox® to the U.S. market.

According to the Complaint, Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc., and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”). Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the FDA.

According to the Complaint, Turquoise Hill Resources Ltd. is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia, which is the Company's principal and only material resource property. Oyu Tolgoi is a combined open pit and underground mining project in the Khanbogd sum, or district, in Mongolia, located in the south Gobi Desert. The site was discovered in 2001 and is currently being developed as a joint venture between Turquoise Hill, which has a 66% ownership stake in the mine, and the Mongolian government, which has a 34% stake.

According to the Complaint, Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat cystic fibrosis.

According to the Complaint, Loop Industries, Inc. is a technology company that purports to own proprietary technology that depolymerizes no- and low-waste PET plastic and polyester fiber. The resulting material is used to create PET resin for food-grade packaging.

According to the Complaint, Mesoblast Limited develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcelL), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.

According to the Complaint, Royal Caribbean Cruises LTD is currently the second largest cruise line company in the world behind Carnival.

According to the Complaint, Precigen, Inc. (formerly known as Intrexon Corporation) purportedly operates in the synthetic biology field and creates biologically-based products. During the Class Period, the Company's securities traded on the New York Stock Exchange under the ticker symbol "XON" until September 25, 2018, when the Company's stock began trading on the NASDAQ market. On February 1, 2020, the Company changed its name to "Precigen, Inc." and its stock symbol to "PGEN."

According to the Complaint, Aurora Cannabis Inc. produces and distributes medical cannabis products worldwide.

According to the Complaint, Credit Acceptance Corporation is a subprime auto finance company providing loans and other related financial products that enable automobile dealers to sell vehicles to consumers. In 2019, Credit Acceptance funded about 370,000 subprime auto loans nation-wide of which over 95% were subprime loans. A substantial portion of Credit Acceptance's loans are never repaid. The Company also securitizes and sells its loans to investors.

According to the Complaint, Montage Resources Corporation is an exploration and production company with approximately 195,000 net effective core undeveloped acres currently focused on the Utica and Marcellus Shales of Southeast Ohio, West Virginia, and North Central Pennsylvania.

According to the Complaint, Pintec Technology Holdings Limited is purportedly a technology platform that enables financial services in China by connecting business partners and financial partners with users.

According to the Complaint, Immunomedics, Inc. is a leader in next-generation antibody-drug conjugate (“ADC”) technology, committed to helping people with hard-to-treat cancers.

According to the Complaint, Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. Tactile's principal area of therapeutic focus is vascular disease, with a goal of advancing the standard of care in treating lymphedema and chronic venous insufficiency.

According to the Complaint, Seacoast Commerce Banc Holdings is a bank holding company with one wholly-owned banking subsidiary, Seacoast Bank. Seacoast Bank has five full-service banking branches in California and Nevada, and loan and deposit production offices throughout Arizona, California, Colorado, Illinois, Indiana, Massachusetts, Michigan, Nevada, Ohio, Oregon, Texas, Utah, and Washington.

According to the Complaint, Peabody Energy Corporation is currently the largest coal mining company in the world, with 23 coal mines throughout the United States and Australia. One of its mines in Australia is the North Goonyella mine, which was acquired by Peabody in 2004 and through which the Company ships coal to customers in India, China and South Korea. As of the start of the Class Period, the North Goonyella mine was considered Peabody's most profitable single operation.

According to the Complaint, Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for the treatment of peanut and other food allergies.

According to the Complaint, Garrett Motion Inc. designs, manufactures and sells turbocharger, electric-boosting and connected vehicle technologies for original equipment manufacturers and the aftermarket. In October 2018, the Company formed as a spin-off of Honeywell’s Transportation Systems business. Garrett’s common stock traded on the New York Stock Exchange under the symbol “GTX” until September 18, 2020 and has traded over-the-counter under the symbol “GTXMQ” since September 21, 2020.

According to the Complaint, BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company's product candidates include, among others, valoctocogene roxaparvovec, an investigational AAV gene therapy, which is in Phase 3 clinical development for the treatment of patients with severe hemophilia A.

According to the Complaint, Rosetta Stone’s language division uses advanced digital technology to help all types of learners read, write, and speak more than thirty languages. Lexia Learning, the Company’s literacy education division, is a leader in the literacy education space. Lexia Learning helps students build fundamental reading skills through its instruction and assessment programs.